ArticleCurrent neuropharmacology2026
Alterations in GABAergic Interneurons, Neuroinflammation, and Epigenetics: Potential Targets for Therapeutic Strategies in Schizophrenia.
Article in Current neuropharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSchizophrenia (SZ) is a long-term psychiatric condition that affects cognition, thought processing, emotional regulation, and behavior. Epigenetic modifications during pregnancy or early postnatal development increase vulnerability to SZ by disrupting the balance of GABAergic-glutamatergic neurotransmission.
objectiveThe association between GABAergic interneurons and inflammation has been increasingly investigated. Systemic inflammation alters the expression of GABAergic interneuron markers, including somatostatin and parvalbumin, in various brain regions. These modifications contribute to microglial reactivity and neuronal damage. Neuroinflammation, driven by reactive microglia, is recognized as a pathophysiological mechanism associated with SZ and its cognitive domain.
methodsIn this review, we addressed the role of GABAergic interneurons and examined how neuroinflammation interacts with epigenetic changes, contributing to SZ development. Network analysis was used to reveal potential molecular targets for pharmacological studies.
resultsFunctional analysis of TLR4 and NF-κB1 revealed molecular factors relevant to inflammatory processes and gene regulation. Network analysis of GABA receptor A type 1 and TNF identified molecular targets suitable for pharmacological intervention. Protein-chemical interaction analysis showed that TLR4 and NF-κB1 interact with the polyphenols quercetin, epigallocatechin gallate, and resveratrol, all of which exert anti-inflammatory effects via epigenetic mechanisms, as well as the HDAC inhibitor valproic acid.
conclusionEpigenetic changes in GABAergic interneurons may facilitate circuit imbalance and exacerbate psychotic symptoms. Epigenetic alterations in cortical parvalbumin-positive GABAergic interneurons and modifications in glutamate-mediated excitatory neurotransmission during early neurodevelopment contribute to the pathogenesis of SZ, alongside concomitant neuroinflammation. Targeting these epigenetic modifications and neuroinflammation may reveal new treatment strategies for the pharmacological management of SZ.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.